keyword
https://read.qxmd.com/read/38055913/genetic-characterization-of-primary-mediastinal-b-cell-lymphoma-pathogenesis-and-patient-outcomes
#21
JOURNAL ARTICLE
Daniel Noerenberg, Franziska Briest, Cornelius Hennch, Kenichi Yoshida, Raphael Hablesreiter, Yasuhide Takeuchi, Hiroo Ueno, Annette M Staiger, Marita Ziepert, Fazila Asmar, Benjamin N Locher, Erika Toth, Thomas Weber, Rose-Marie Amini, Wolfram Klapper, Maria Bouzani, Viola Poeschel, Andreas Rosenwald, Gerhard Held, Elías Campo, Naveed Ishaque, Kostas Stamatopoulos, George Kanellis, Ioannis Anagnostopoulos, Lars Bullinger, Neta Goldschmidt, Pier Luigi Zinzani, Csaba Bödör, Richard Rosenquist, Theodoros P Vassilakopoulos, German Ott, Seishi Ogawa, Frederik Damm
PURPOSE: Primary mediastinal large B-cell lymphoma (PMBCL) is a rare aggressive lymphoma predominantly affecting young female patients. Large-scale genomic investigations and genetic markers for risk stratification are lacking. PATIENTS AND METHODS: To elucidate the full spectrum of genomic alterations, samples from 340 patients with previously untreated PMBCL were investigated by whole-genome (n = 20), whole-exome (n = 78), and targeted (n = 308) sequencing. Statistically significant prognostic variables were identified using a multivariable Cox regression model and confirmed by L1/L2 regularized regressions...
February 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38045327/enhancer-regulatory-networks-globally-connect-non-coding-breast-cancer-loci-to-cancer-genes
#22
Yihan Wang, Daniel Armendariz, Lei Wang, Huan Zhao, Shiqi Xie, Gary C Hon
Genetic studies have associated thousands of enhancers with breast cancer. However, the vast majority have not been functionally characterized. Thus, it remains unclear how variant-associated enhancers contribute to cancer. Here, we perform single-cell CRISPRi screens of 3,512 regulatory elements associated with breast cancer to measure the impact of these regions on transcriptional phenotypes. Analysis of >500,000 single-cell transcriptomes in two breast cancer cell lines shows that perturbation of variant-associated enhancers disrupts breast cancer gene programs...
November 20, 2023: bioRxiv
https://read.qxmd.com/read/38041093/the-enrichment-of-fanconi-anemia-homologous-recombination-pathway-aberrations-in-atm-atr-mutated-nsclc-was-accompanied-by-unique-molecular-features-and-poor-prognosis
#23
JOURNAL ARTICLE
Wei Wei, Fangfang Shi, Yang Xu, Yang Jiao, Ying Zhang, Qiuxiang Ou, Xue Wu, Lingyi Yang, Jinhuo Lai
BACKGROUND: ATM and ATR are two critical factors to regulate DNA damage response (DDR), and their mutations were frequently observed in different types of cancer, including non-small cell lung cancer (NSCLC). Given that the majority of identified ATM/ATR mutations were variants of uncertain significance, the clinical/molecular features of pathogenic ATM/ATR aberrations have not been comprehensively investigated in NSCLC. METHODS: Next-generation sequencing (NGS) analyses were conducted to investigate the molecular features in 191 NSCLC patients who harbored pathogenic/likely pathogenic ATM/ATR mutations and 308 NSCLC patients who did not have any types of ATM/ATR variants...
December 1, 2023: Journal of Translational Medicine
https://read.qxmd.com/read/38030304/tp53-mtorc1-mediated-bidirectional-regulation-of-pd-l1-modulates-immune-evasion-in-hepatocellular-carcinoma
#24
JOURNAL ARTICLE
Jiongjie Yu, Sunbin Ling, Jiachen Hong, Lincheng Zhang, Wei Zhou, Lu Yin, Shengjun Xu, Qingyang Que, Yongfeng Wu, Qifan Zhan, Jiaqi Bao, Nan Xu, Yuchen Liu, Kangchen Chen, Xuyong Wei, Zhikun Liu, Tingting Feng, Lin Zhou, Haiyang Xie, Shuai Wang, Jimin Liu, Shusen Zheng, Xiao Xu
BACKGROUND: Immunotherapy has facilitated great breakthroughs in the treatment of hepatocellular carcinoma (HCC). However, the efficacy and response rate of immunotherapy are limited and vary among different patients with HCC. TP53 mutation substantially affects the expression of immune checkpoint molecules in multiple cancers. However, the regulatory relationship between programmed death ligand 1 (PD-L1) and TP53 is poorly studied in HCC. We aimed to elucidate the regulatory mechanism of PD-L1 in HCC with different TP53 statuses and to assess its role in modulating immune evasion in HCC...
November 29, 2023: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38024632/prognostic-heterogeneity-and-clonal-dynamics-within-distinct-subgroups-of-myelodysplastic-syndrome-and-acute-myeloid-leukemia-with-tp53-disruptions
#25
JOURNAL ARTICLE
Shyam A Patel, Jan Cerny, William K Gerber, Muthalagu Ramanathan, Asiri Ediriwickrema, Benjamin Tanenbaum, Lloyd Hutchinson, Xiuling Meng, Julie Flahive, Bruce Barton, Andrew J Gillis-Smith, Sakiko Suzuki, Salwa Khedr, William Selove, Anne W Higgins, Patricia M Miron, Karl Simin, Bruce Woda, Jonathan M Gerber
TP53 aberrations constitute the highest risk subset of myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The International Consensus Classification questions the blast threshold between MDS and AML. In this study, we assess the distinction between MDS and AML for 76 patients with TP53 aberrations. We observed no significant differences between MDS and AML regarding TP53 genomics. Median overall survival (OS) was 223 days for the entire group, but prognostic discrimination within subgroups showed the most inferior OS (46 days) for AML with multihit allelic state plus TP53 variant allele frequency (VAF) > 50%...
November 2023: EJHaem
https://read.qxmd.com/read/38019903/enhanced-tp53-reactivation-disrupts-myc-transcriptional-program-and-overcomes-venetoclax-resistance-in-acute-myeloid-leukemias
#26
JOURNAL ARTICLE
Yuki Nishida, Jo Ishizawa, Edward Ayoub, Rafael Heinz Montoya, Lauren B Ostermann, Muharrem Muftuoglu, Vivian R Ruvolo, Tallie Patsilevas, Darah A Scruggs, Shayaun Khazaei, Po Yee Mak, Wenjing Tao, Bing Z Carter, Steffen Boettcher, Benjamin L Ebert, Naval G Daver, Marina Konopleva, Takahiko Seki, Kensuke Kojima, Michael Andreeff
The tumor suppressor TP53 is frequently inactivated in a mutation-independent manner in cancers and is reactivated by inhibiting its negative regulators. We here cotarget MDM2 and the nuclear exporter XPO1 to maximize transcriptional activity of p53. MDM2/XPO1 inhibition accumulated nuclear p53 and elicited a 25- to 60-fold increase of its transcriptional targets. TP53 regulates MYC , and MDM2/XPO1 inhibition disrupted the c-MYC-regulated transcriptome, resulting in the synergistic induction of apoptosis in acute myeloid leukemia (AML)...
December 2023: Science Advances
https://read.qxmd.com/read/38010733/disruption-of-the-tp53-locus-in-osteosarcoma-leads-to-tp53-promoter-gene-fusions-and-restoration-of-parts-of-the-tp53-signalling-pathway
#27
JOURNAL ARTICLE
Karim H Saba, Valeria Difilippo, Michal Kovac, Louise Cornmark, Linda Magnusson, Jenny Nilsson, Hilda van den Bos, Diana Cj Spierings, Mahtab Bidgoli, Tord Jonson, Vaiyapuri P Sumathi, Otte Brosjö, Johan Staaf, Floris Foijer, Emelie Styring, Michaela Nathrath, Daniel Baumhoer, Karolin H Nord
TP53 is the most frequently mutated gene in human cancer. This gene shows not only loss-of-function mutations but also recurrent missense mutations with gain-of-function activity. We have studied the primary bone malignancy osteosarcoma, which harbours one of the most rearranged genomes of all cancers. This is odd since it primarily affects children and adolescents who have not lived the long life thought necessary to accumulate massive numbers of mutations. In osteosarcoma, TP53 is often disrupted by structural variants...
November 27, 2023: Journal of Pathology
https://read.qxmd.com/read/38002884/an-asymptomatic-ectopic-mass-as-a-presentation-of-adrenocortical-carcinoma-due-to-a-novel-germline-tp53-p-phe338leu-tetramerisation-domain-variant
#28
Justyna Walenciak, Zuzanna Urbanska, Agata Pastorczak, Katarzyna Babol-Pokora, Kamila Wypyszczak, Ewa Bien, Aleksandra Gawlowska-Marciniak, Jozef Kobos, Wieslawa Grajkowska, Joanna Smyczynska, Wojciech Mlynarski, Szymon Janczar
Adrenocortical carcinoma (ACC) is a rare cancer in childhood. ACC is frequently associated with germline TP53 variants, with founder effects especially due to the p.Arg337His mutation. ACC leads to the secretion of adrenocortical hormones, resulting in endocrine syndromes, which is the usual trigger for establishing the diagnosis. We present a surprising ACC pathology in a non-secreting, ectopic retroperitoneal tumour in a 4-year-old boy, successfully controlled with chemotherapy and mitotane after microscopically incomplete tumour resection with spillage...
November 7, 2023: Children
https://read.qxmd.com/read/37941034/cytogenomic-features-of-richter-transformation
#29
JOURNAL ARTICLE
Renata Woroniecka, Grzegorz Rymkiewicz, Zbigniew Bystydzienski, Barbara Pienkowska-Grela, Jolanta Rygier, Natalia Malawska, Katarzyna Wojtkowska, Nikolina Goral, Katarzyna Blachnio, Marcin Chmielewski, Magdalena Bartnik-Glaska, Beata Grygalewicz
BACKGROUND: Richter transformation (RT) is the development of aggressive lymphoma in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This rare disease is characterised by dismal prognosis. In recent years, there has been a deeper understanding of RT molecular pathogenesis, and disruptions of apoptosis (TP53) and proliferation (CDKN2A, MYC, NOTCH1) has been described as typical aberrations in RT. RESULTS: A single-institution cohort of 33 RT patients were investigated by karyotyping, fluorescence in situ hybridization and single nucleotide polymorphism/copy number (CN) arrays...
November 8, 2023: Molecular Cytogenetics
https://read.qxmd.com/read/37937506/targeting-tp53-disruption-in-chronic-lymphocytic-leukemia-current-strategies-and-future-directions
#30
REVIEW
Stefano Molica, Constantine Tam, David Allsup, Aaron Polliack
In the modern era of Chronic Lymphocytic Leukemia (CLL) targeted therapy, the loss of p53 function due to genetic abnormalities remains a significant challenge. This is because even targeted agents, which are currently the mainstay of treatment for CLL, do not directly target p53 or restore its disrupted pathway. Consequently, resistance to therapy and unfavorable clinical outcomes often accompany these p53-related abnormalities. An essential goal of future clinical research should be to address the ostensibly "undruggable" p53 pathway...
November 8, 2023: Hematological Oncology
https://read.qxmd.com/read/37935422/erxian-decoction-induced-serum-exosomes-slowed-bone-marrow-mesenchymal-stem-cell-senescence-through-mitophagy
#31
JOURNAL ARTICLE
Haoqiang Huang, Yinhua Qian, Ye Feng, Yitao Wang, Pingkang Qian, Feng Xu, Qing Wang
OBJECTIVE: Erxian Decoction (EXD) is traditionally employed in the treatment of menopausal syndromes, although its underlying mechanisms remain largely undefined. Given that the senescence of bone marrow mesenchymal stem cells (BMSCs) is intertwined with organismal aging and associated diseases, this study endeavored to elucidate the influence of EXD on aging BMSCs and uncover the mechanisms through which EXD impedes BMSC senescence. METHODS: Initially, we probed the anti-senescent mechanisms of EXD on BMSCs via network pharmacology...
November 7, 2023: Journal of Gene Medicine
https://read.qxmd.com/read/37904990/-ataxia-telangiectasia-mutated-atm-disruption-sensitizes-spatially-directed-h3-3k27m-tp53-diffuse-midline-gliomas-to-radiation-therapy
#32
Avani Mangoli, Sophie Wu, Harrison Q Liu, Michael Aksu, Vaibhav Jain, Bronwen E Foreman, Joshua A Regal, Loren B Weidenhammer, Connor E Stewart, Maria E Guerra Garcia, Emily Hocke, Karen Abramson, Nerissa T Williams, Lixia Luo, Katherine Deland, Laura Attardi, Kouki Abe, Rintaro Hashizume, David M Ashley, Oren J Becher, David G Kirsch, Simon G Gregory, Zachary J Reitman
Diffuse midline gliomas (DMGs) are lethal brain tumors characterized by p53-inactivating mutations and oncohistone H3.3K27M mutations that rewire the cellular response to genotoxic stress, which presents therapeutic opportunities. We used RCAS/tv-a retroviruses and Cre recombinase to inactivate p53 and induce K27M in the native H3f3a allele in a lineage- and spatially-directed manner, yielding primary mouse DMGs. Genetic or pharmacologic disruption of the DNA damage response kinase Ataxia-telangiectasia mutated (ATM) enhanced the efficacy of focal brain irradiation, extending mouse survival...
October 20, 2023: bioRxiv
https://read.qxmd.com/read/37865506/diagnosis-and-classification-of-myelodysplastic-syndromes-with-mutated-tp53
#33
REVIEW
Alexa J Siddon, Olga K Weinberg
The genetic underpinnings of myeloid neoplasms are becoming increasingly well understood. The accessibility to sequencing technology, in particular next-generation sequencing (NGS), has highlighted the importance of gene mutations in myelodysplastic syndromes (MDS) in conjunction with traditional cytogenetics. With the relatively recent influx of molecular information to complement known cytogenetic abnormalities, the diagnosis, classification, and prognosis of MDS and acute myeloid leukemia (AML) have been increasingly refined, which has also led to therapeutic advancements...
December 2023: Clinics in Laboratory Medicine
https://read.qxmd.com/read/37752286/del-8p-and-tnfrsf10b-loss-are-associated-with-a-poor-prognosis-and-resistance-to-fludarabine-in-chronic-lymphocytic-leukemia
#34
JOURNAL ARTICLE
Ludovic Jondreville, Lea Dehgane, Cecile Doualle, Luce Smagghe, Beatrice Grange, Frederic Davi, Leticia K Lerner, Delphine Garnier, Clotilde Bravetti, Olivier Tournilhac, Damien Roos-Weil, Marouane Boubaya, Elise Chapiro, Santos A Susin, Florence Nguyen-Khac
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease, the prognosis of which varies according to the cytogenetic group. We characterized a rare chromosomal abnormality (del(8p), deletion of the short arm of chromosome 8) in the context of CLL. By comparing the largest cohort of del(8p) CLL to date (n = 57) with a non-del(8p) cohort (n = 155), del(8p) was significantly associated with a poor prognosis, a shorter time to first treatment, worse overall survival (OS), and a higher risk of Richter transformation...
September 26, 2023: Leukemia
https://read.qxmd.com/read/37715172/targeting-wee1-kinase-as-a-p53-independent-therapeutic-strategy-in-high-risk-and-relapsed-acute-lymphoblastic-leukemia
#35
JOURNAL ARTICLE
Hayden L Bell, Helen J Blair, Mankaran Singh, Anthony V Moorman, Olaf Heidenreich, Frederik W van Delft, John Lunec, Julie A E Irving
BACKGROUND: Outcomes for patients with relapsed acute lymphoblastic leukemia (ALL) are poor and there is a need for novel therapies to improve outcomes. Targeted inhibition of WEE1 with small-molecule inhibitor adavosertib (AZD1775) has emerged as a therapeutic strategy to sensitize cancer cells to DNA-damaging chemotherapeutics, particularly in the context of TP53-mutated tumors. However, WEE1 inhibition as a potential therapeutic strategy for patients with high-risk and relapsed ALL, including those with TP53 mutations, has not been definitively evaluated...
September 15, 2023: Cancer Cell International
https://read.qxmd.com/read/37714156/mitotic-perturbation-is-a-key-mechanism-of-action-of-decitabine-in-myeloid-tumor-treatment
#36
JOURNAL ARTICLE
Tomohiro Yabushita, Takumi Chinen, Atsuya Nishiyama, Shuhei Asada, Ruka Shimura, Tomoya Isobe, Keita Yamamoto, Naru Sato, Yutaka Enomoto, Yosuke Tanaka, Tomofusa Fukuyama, Hitoshi Satoh, Keiko Kato, Kaori Saitoh, Takamasa Ishikawa, Tomoyoshi Soga, Yasuhito Nannya, Tatsuo Fukagawa, Makoto Nakanishi, Daiju Kitagawa, Toshio Kitamura, Susumu Goyama
Decitabine (DAC) is clinically used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Our genome-wide CRISPR-dCas9 activation screen using MDS-derived AML cells indicates that mitotic regulation is critical for DAC resistance. DAC strongly induces abnormal mitosis (abscission failure or tripolar mitosis) in human myeloid tumors at clinical concentrations, especially in those with TP53 mutations or antecedent hematological disorders. This DAC-induced mitotic disruption and apoptosis are significantly attenuated in DNMT1-depleted cells...
September 12, 2023: Cell Reports
https://read.qxmd.com/read/37672936/effects-of-concurrent-tp53-mutations-on-the-efficacy-and-prognosis-of-targeted-therapy-for-advanced-egfr-mutant-lung-adenocarcinoma
#37
JOURNAL ARTICLE
Huiwen Qian, Chunqi Hou, Yi Zhang, Shundong Ji, Chongke Zhong, Juan Li, Qianqian Zhang, Jianan Huang, Chong Li, ChengJi
BACKGROUND: How concurrent TP53 mutations affect targeted therapy of advanced Epidermal Growth Factor Receptor (EGFR) mutant lung adenocarcinoma remains controversial, particularly the deep classification of TP53 mutations. METHODS: This study retrospectively analyzed the clinical data of advanced EGFR mutant lung adenocarcinoma patients treated with EGFR-tyrosine kinase inhibitors (TKIs) in the First Affiliated Hospital of Soochow University. The survival rates were compared using Log-rank tests...
November 2023: Cancer Genetics
https://read.qxmd.com/read/37671809/disruption-of-caspase-independent-cell-proliferation-pathway-on-spheroids-hela-cells-treated-with-curcumin
#38
JOURNAL ARTICLE
Liana Martins de Oliveira, Luan Vitor Alves de Lima, Matheus Felipe da Silva, Ingrid Felicidade, Sandra Regina Lepri, Mário Sérgio Mantovani
Curcumin is an antiproliferative phytochemical extracted from Curcuma longa L and which has been studied in preclinical drug screening using cell monolayers and animal models. However, several limitations of these culture systems may be overcome by performing screening with three-dimensional (3-D) cell culture. The aim of this study was to investigate the effects of curcumin on cytotoxicity and genotoxicity as well as spheroid growth using cervical adenocarcinoma HeLa cell spheroids by performing RT-PCR mRNA expression of genes involved in cell death ( CASP3 , CASP8 , CASP9 , PARP1 , BBC3 , BIRC5 , BCL2 , TNF ), autophagy ( BECN1, SQSTM1 ), cell cycle regulation ( TP53 , C-MYC , NF-kB , CDKN1A , m-TOR , TRAF-2 ), DNA damage repair ( H2AFX , GADD45A, GADD45G ), oxidative stress ( GPX1 ), reticulum stress ( EIF2AK3, ERN1 ), and invasion ( MMP1 , MMP9 ) was investigated...
September 6, 2023: Journal of Toxicology and Environmental Health. Part A
https://read.qxmd.com/read/37568719/clinical-characteristics-and-outcomes-of-patients-with-primary-and-secondary-myelofibrosis-according-to-the-genomic-classification-using-targeted-next-generation-sequencing
#39
JOURNAL ARTICLE
Marta Garrote, Mónica López-Guerra, Eduardo Arellano-Rodrigo, María Rozman, Sara Carbonell, Francesca Guijarro, Marta Santaliestra, Ana Triguero, Dolors Colomer, Francisco Cervantes, Alberto Álvarez-Larrán
Myelofibrosis (MF) is a heterogeneous disease regarding its mutational landscape, clinical presentation, and outcomes. The aim of our work is to evaluate the genomic classification of MF considering whether it is primary or secondary. One-hundred seventy-five patients, 81 with primary MF (PMF) and 94 with secondary MF (SMF) were hierarchically allocated into eight molecular groups. We found that TP53 disruption/aneuploidy ( n = 16, 9%) was more frequent (12% versus 6%) and showed higher allele burden (57% versus 15%, p = 0...
July 31, 2023: Cancers
https://read.qxmd.com/read/37553320/p53-isoform-expression-promotes-a-stemness-phenotype-and-inhibits-doxorubicin-sensitivity-in-breast-cancer
#40
JOURNAL ARTICLE
Luiza Steffens Reinhardt, Kira Groen, Xiajie Zhang, Brianna C Morten, Anna Wawruszak, Kelly A Avery-Kiejda
In breast cancer, dysregulated TP53 expression signatures are a better predictor of chemotherapy response and survival outcomes than TP53 mutations. Our previous studies have shown that high levels of Δ40p53 are associated with worse disease-free survival and disruption of p53-induced DNA damage response in breast cancers. Here, we further investigated the in vitro and in vivo implications of Δ40p53 expression in breast cancer. We have shown that genes associated with cell differentiation are downregulated while those associated with stem cell regulation are upregulated in invasive ductal carcinomas expressing high levels of Δ40p53...
August 8, 2023: Cell Death & Disease
keyword
keyword
112276
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.